Anti-AMR antibiotics

New-generation antibiotics mostly work by pairing a beta-lactam core (a cephalosporin or related structure) with a next-generation beta-lactamase inhibitor that blocks the enzymes resistant bacteria use to destroy the antibiotic, or by re-engineering an existing antibiotic class to evade known resistance mechanisms. The field’s economics are notoriously difficult — a novel antibiotic is used sparingly by design (stewardship keeps it in reserve for resistant infections), which caps peak sales far below what the R&D cost would justify — so most of the companies here are small, specialist developers rather than large pharma. 2026 has shown both how far the field has come and how fragile that progress still is: Wockhardt’s zidebactam-cefepime combination (Zaynich) is under FDA fast-track review and EMA accelerated assessment as the first India-developed antibiotic to reach this stage globally, while Venatorx’s cefepime-taniborbactam received an FDA Complete Response Letter over manufacturing data — not efficacy — after its GARDP development partnership had already ended.

The key directions are:

1. Beta-lactam / beta-lactamase-inhibitor combinations: Pairing a cephalosporin with a next-generation inhibitor active against serine- and metallo-beta-lactamases, the resistance enzymes that inactivate older combinations.
2. Re-engineered legacy classes: Modifying an established antibiotic scaffold (tetracyclines, siderophore-conjugated cephalosporins) to restore activity against strains that have evolved resistance to the parent class.
3. Domestic manufacturing resilience: Onshoring API and finished-dose production for a novel antibiotic, treated as a supply-security issue given how concentrated global antibiotic manufacturing has become.
4. Access and stewardship commitments: Structuring pricing and distribution (including for low- and middle-income countries) so a new antibiotic is actually used only where resistance demands it, rather than driving the resistance it was built to fight.

Sectoral value chain#

[Target resistance mechanism ID] ──> [Candidate synthesis & optimization] ──> [Clinical trials vs. resistant pathogens] ──> [Regulatory review]
                                  │
                          (CMC & manufacturing scale-up)
                                  │
                                  ▼
[Stewardship-gated distribution] <─── [Commercial launch] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Metallo-beta-lactamase inhibition: A harder chemistry problem than inhibiting serine beta-lactamases, since metallo-enzymes use a different catalytic mechanism — several of this decade’s candidates are built specifically to close this gap.
• Siderophore-conjugation: Attaching an antibiotic to an iron-chelating siderophore so bacteria’s own iron-uptake channels pull the drug across their outer membrane, the mechanism behind Shionogi’s cefiderocol.
• CMC-first development: Building out commercial-scale, ideally domestic, manufacturing capability in parallel with clinical development rather than after approval, in response to well-publicized antibiotic supply-chain fragility.

The stack centers on two hard chemistry problems — inhibiting the enzymes that inactivate beta-lactams, and getting a drug across a Gram-negative bacterium’s outer membrane at all — plus the CMC and stewardship infrastructure that decides whether a scientifically sound candidate actually reaches patients.

1. Metallo-Beta-Lactamase Inhibition:
   • Boronic-acid-based inhibitors (the taniborbactam class) are designed to cover metallo-beta-lactamases, which use a zinc-dependent mechanism that most first-generation inhibitors (built for serine enzymes) cannot touch.
2. Beta-Lactam Enhancer Mechanisms:
   • Wockhardt’s zidebactam acts as a “beta-lactam enhancer,” binding penicillin-binding protein 2 to trigger bacterial cell death independent of the classic beta-lactamase-inhibition route, intended to stay active even against some carbapenem-resistant strains.
3. Siderophore-Mediated Uptake:
   • Cefiderocol is conjugated to a catechol siderophore, exploiting the iron-starved bacterium’s own TonB-dependent iron transporters to actively pull the drug across the outer membrane rather than relying on passive porin diffusion.